Fig. 4From: Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinomaOverall survival: group 1 (cTACE) vs. group 2 (DEB-TACE), differentiated by status of portal invasion. P-values were 0.82 for patients with and 0.48 for patients without portal invasion. “I” denotes censored valuesBack to article page